Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimization.
Anticancer drugs
HDAC inhibitors
HDAC6
Immune therapy
Journal
Seminars in cell & developmental biology
ISSN: 1096-3634
Titre abrégé: Semin Cell Dev Biol
Pays: England
ID NLM: 9607332
Informations de publication
Date de publication:
15 Feb 2024
15 Feb 2024
Historique:
received:
20
07
2022
revised:
03
09
2022
accepted:
04
09
2022
pubmed:
21
9
2022
medline:
21
9
2022
entrez:
20
9
2022
Statut:
ppublish
Résumé
Histone deacetylases (HDACs) are promising targets for the design of anticancer drugs. HDAC6 is of particular interest since it is a cytoplasmic HDAC regulating the acetylation state of cancer-relevant cytoplasmic proteins such as tubulin, Hsp90, p53, and others. HDAC6 also influences the immune system, and the combination of HDAC6 inhibitors with immune therapy showed promising anticancer results. In addition, the design of new HDAC6 inhibitors led to potent anticancer drugs with immunomodulatory activities. This review describes the current state of play, and the recent developments in the research on the interactions of HDAC6 inhibitors with the immune system, and the development of new HDAC6 inhibitors with immunomodulatory activities to improve the therapy options for cancer patients.
Identifiants
pubmed: 36127263
pii: S1084-9521(22)00271-3
doi: 10.1016/j.semcdb.2022.09.009
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
286-294Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.